UNSPSC 51101672: Nemadectin

This classification denotes an antiparasitic agent with the molecular formula C36H52O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1Y8VJ1G3TY, chemically known as milbemycin b, 5-o-demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-hydroxy-, (6r,23s,25s(e))- but generally known as nemadectin, which bears US NIH Compound Identifier 6436124. European Medicines Agency schedules Nemadectin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09189MIG.

UNSPSC 51101672 Nemadectin (Commodity) represents pharmaceutical products and related medical supplies that state and local health departments and county public health agencies procure through competitive bidding and cooperative purchasing vehicles. The code encompasses antiparasitic pharmaceuticals and emergency medical supplies including naloxone (opioid-reversal agents) and drug deactivation systems, which state and local governments are actively acquiring to support community health initiatives and emergency response programs.

Illinois Department of Public Health and Seminole County, Florida represent the recent issuing bodies active under this code, reflecting state health departments and county-level public health authorities as the primary procurement bodies. The Illinois Department of Public Health awarded a $2,999,999.11 three-year pharmaceutical warehouse piggyback contract through the MMCAP Infuse cooperative purchasing consortium to Chartwell Rx LLC in August 2026 for supply of Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets through an Invitation for Bid process. Seminole County, Florida released an IFB on June 30, 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the bid deadline was July 26, 2023, with fixed-fee pricing and a two-year initial term plus one-year renewal option. Recent activity concentrates in Florida and Illinois; no set-aside designations were identified in either solicitation, and both awards emphasize competitive pricing and vendor compliance with drug-free workplace and E-Verify requirements.